COVID19
Figure 1 shows the most prevalent events adverse events reported in VAERS for all COVID19 vaccines. The EBGM values near 1.0 suggest that the risk of experiencing these is similar to that of any other vaccine in the time period. The number of cases is high because each patient can report several of these events.
Figure 2 shows selected significant cardiovascular events reported for COVID19 vaccine, stratified by age ranges to show age-related differences in risk. The EBGM values reflect the risk above all other vaccines in the time period, and values above 2.0 are considered significant.
One can see from Figure 2 that the age range 60-80 may have a safety signal for these cardiovascular issues, while older and younger age ranges have EGBM values below the cutoff level of 2.0. With all ages combined the EBGM values also suggest signs of safety issues even with stratification by age, however these can be attributed mostly to the results from the 60-80 age group.
Figure 3 shows the counts used in the 2x2 tables that relate COVID19 vaccine to pulmonary embolism and acute myocardial infarction in the 60-80 age group, the figures reflecting the number of patients in each category.
Influenza
As a comparative control the same process was applied to the influenza FLU3 (trivalent) vaccine type, which has the most vaccine event reports in VAERS in the time period studied. The most common events associated with FLU3 vaccines are shown in Figure 4. As with COVID19 vaccines, these are common but not specifically more so for FLU3 than for other vaccines, as indicated by EBGM values close to 1.0.
Figure 5 shows the 2x2 table for pulmonary embolism associated with FLU3 vaccine for the 60-80 year age range for comparison with the COVID19 data in Figure 3. The EBGM .05 value for this association is far below the threshold for significance at 0.23. (EBGM 0.5 is 0.56) The comparison with all other vaccines administered to patients in this age range suggests that it is less likely than other vaccines to be associated with this issue. The median age for all FLU3 recipients is older than COVID19 recipients at 69 years, vs 48 years for COVID19. Thus the difference cannot be attributed solely to the difference in age distributions of the patient populations.